Blood-Brain Barrier (BBB) Model Development Services

The blood-brain barrier excludes the majority of systemically administered therapeutics from the central nervous system. Tight junctions between brain endothelial cells eliminate the paracellular route, efflux transporters return many compounds that do cross back to the circulation, and the net result is that a molecule with excellent plasma exposure may achieve brain concentrations too low to engage its target. For central nervous system programs this is the first question to answer, not the last, because a compound that cannot reach the brain will produce a null efficacy result that says nothing about its pharmacology.

Altogen Labs provides blood-brain barrier model development and study services for programs requiring evaluation of central nervous system exposure, barrier permeability, or delivery across the barrier. Model selection and study design are tailored to the molecule, delivery approach, biological question, and required analytical endpoint rather than drawn from a fixed protocol. To discuss a central nervous system delivery question, request a quote.

Study design

Blood-brain barrier studies evaluate permeability, tissue distribution, delivery strategies, and biological activity in central nervous system directed programs. The experimental system may incorporate in vitro barrier components, in vivo pharmacology, or both, depending on the objective.

The distinction that matters most in design is between measuring whether a compound enters the brain and measuring whether it does anything once there. Brain concentration establishes exposure. Target engagement in brain tissue establishes that the exposure achieved is pharmacologically meaningful. A compound can satisfy the first and fail the second, and a study designed only around concentration will not reveal it.

Where free rather than total brain concentration is the relevant measure, because protein and tissue binding reduce the fraction available to engage the target, this should be stated in the objectives at the outset, since it affects sample handling and the analytical approach.

Delivery and biodistribution

For nucleic acid and other delivery programs, barrier studies integrate with formulation, in vivo delivery, biodistribution, and tissue collection to determine whether a delivery strategy reaches the intended central nervous system compartment. This matters because delivery vehicle and payload can distribute differently, and a formulation that accumulates in brain tissue has not necessarily released an active payload into the relevant cells.

The peripheral organ panel is collected alongside brain tissue rather than as an afterthought, since the proportion of an administered dose diverted to liver, spleen, and kidney is usually the explanation for low brain accumulation, and knowing which compartment captured the material directs the next formulation iteration.

Downstream analysis

Applicable endpoints include tissue concentration and distribution measurements, gene expression analysis for target knockdown in brain tissue, protein analysis, imaging, histological evaluation, and other protocol-defined readouts. Study-specific methods and acceptance criteria are established before initiation.

Applied examples

Exposure before efficacy. A candidate intended for a brain indication is assessed for brain and plasma concentration at matched timepoints before any efficacy study is commissioned, establishing whether brain exposure is sufficient to justify the larger study.

Formulation iteration. Two delivery formulations are compared for brain accumulation against a peripheral organ panel, identifying which achieves the higher brain to liver ratio and directing formulation development before efficacy animals are committed.

Knockdown in brain tissue. A formulated nucleic acid is administered and brain tissue assessed for both vehicle accumulation and target transcript reduction, distinguishing a formulation that reached the brain but failed to release its payload from one that never arrived.

Model flexibility and program-specific design

No single barrier cell system, host background, or permeability method is applied across all projects. The relevant model depends on whether the question concerns passive permeability, active transport, receptor-mediated transcytosis, or delivery vehicle behavior, and these require different experimental systems. Study design is developed for the program rather than adapted from a standard protocol, and the limitations of the chosen system are stated in the report rather than left implicit. All in vivo procedures are conducted under active IACUC protocols. GLP standards are applied where a study is formally designated as GLP.

Send molecule type, delivery approach, and target region, or request a quote.